ATE218343T1 - Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva - Google Patents

Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva

Info

Publication number
ATE218343T1
ATE218343T1 AT96923693T AT96923693T ATE218343T1 AT E218343 T1 ATE218343 T1 AT E218343T1 AT 96923693 T AT96923693 T AT 96923693T AT 96923693 T AT96923693 T AT 96923693T AT E218343 T1 ATE218343 T1 AT E218343T1
Authority
AT
Austria
Prior art keywords
anticonvulsives
pyridinamines
pyrrol
unsubstituted
substituted
Prior art date
Application number
AT96923693T
Other languages
English (en)
Inventor
Francis P Huger
Sathapana Kongsamut
Craig P Smith
Lei Tang
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE218343T1 publication Critical patent/ATE218343T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96923693T 1995-07-27 1996-07-08 Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva ATE218343T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50807195A 1995-07-27 1995-07-27
PCT/US1996/011408 WO1997004777A1 (en) 1995-07-27 1996-07-08 Use off unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents

Publications (1)

Publication Number Publication Date
ATE218343T1 true ATE218343T1 (de) 2002-06-15

Family

ID=24021262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923693T ATE218343T1 (de) 1995-07-27 1996-07-08 Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva

Country Status (19)

Country Link
EP (1) EP0840609B1 (de)
JP (1) JP4189029B2 (de)
KR (1) KR100445629B1 (de)
CN (1) CN1184969C (de)
AR (1) AR003471A1 (de)
AT (1) ATE218343T1 (de)
AU (1) AU696007B2 (de)
CA (1) CA2225156C (de)
DE (1) DE69621617T2 (de)
DK (1) DK0840609T3 (de)
ES (1) ES2174081T3 (de)
IL (1) IL122845A0 (de)
MX (1) MX9800774A (de)
NO (1) NO315148B1 (de)
NZ (1) NZ312577A (de)
PT (1) PT840609E (de)
TW (1) TW464497B (de)
WO (1) WO1997004777A1 (de)
ZA (1) ZA966254B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
FR2897614B1 (fr) * 2006-02-20 2008-05-23 Urogene Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032599A (en) * 1986-11-12 1991-07-16 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-l-yl)pyridinamines
EP0287982B1 (de) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US5179099A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-dihydro-1-(pyridinylamino)-indoles
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder

Also Published As

Publication number Publication date
WO1997004777A1 (en) 1997-02-13
AU696007B2 (en) 1998-08-27
IL122845A0 (en) 1998-08-16
CA2225156C (en) 2003-06-10
KR100445629B1 (ko) 2004-10-14
ES2174081T3 (es) 2002-11-01
KR19990035973A (ko) 1999-05-25
NZ312577A (en) 1999-08-30
HK1015687A1 (en) 1999-10-22
NO980334D0 (no) 1998-01-26
NO315148B1 (no) 2003-07-21
AU6454796A (en) 1997-02-26
CN1191486A (zh) 1998-08-26
JPH11510159A (ja) 1999-09-07
JP4189029B2 (ja) 2008-12-03
ZA966254B (en) 1997-02-11
EP0840609A1 (de) 1998-05-13
CA2225156A1 (en) 1997-02-13
PT840609E (pt) 2002-10-31
DE69621617D1 (de) 2002-07-11
MX9800774A (es) 1998-04-30
NO980334L (no) 1998-03-26
DE69621617T2 (de) 2003-01-02
TW464497B (en) 2001-11-21
AR003471A1 (es) 1998-08-05
DK0840609T3 (da) 2002-09-30
EP0840609B1 (de) 2002-06-05
CN1184969C (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
DE69634822D1 (de) Amid-verbindungen und ihre anwendung
DE69431880D1 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DE69607474D1 (de) Anordnung von elektrode und anschlussklemme
DE69634142D1 (de) Neuartige affinitatsliganden und ihre verwendung
DE69636313D1 (de) Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen
DE69325451D1 (de) Verwendung von pyruvamid und ausgewählten pyruvyl-aminosäuren
DE69430662D1 (de) Zusammensetzungen von fluorkohlenwasserstoffen und kohlenwasserstoffen
DE69513307D1 (de) Zusammensetzung und verwendung
DE59507427D1 (de) Mischkristalle und feste Lösungen von 1,4-Diketopyrrolopyrrolen
DE69626729D1 (de) Kombination von Datenwerten
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
DE59708905D1 (de) Injektionsformulierungen von avermectinen und milbemycinen
DE69418203D1 (de) Zementiermittel und ihre verwendung
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE69827393D1 (de) Kosmetische verwendung von bis-resorcinol-triazinderivaten
NO965564D0 (no) Medisinsk anvendelse av bromelain
DE59606486D1 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69808266D1 (de) Herstellung und verwendung von alpha-ketoamid derivate und anordnunge
DE69717677D1 (de) Koproduktion von perfluormethylperfluorvinylether und perfluorethylperfluorvinylether
DE69811500D1 (de) Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum
DE69834227D1 (de) Erkennung und Korrektion von Farblücken
ATE233569T1 (de) Verwendung von proteine als mittel gegen autoimmunekrankheiten
DE59307396D1 (de) Dichtring und verwendung desselben
DE69629027D1 (de) Kosmetische zubereitung zur prävention und beseitigung von hautschäden
DE69719750D1 (de) Kosmetische haarwaschmittel und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee